INmune Historical Income Statement

INMB Stock  USD 4.88  0.08  1.67%   
Historical analysis of INmune Bio income statement accounts such as Total Revenue of 147.2 K or Gross Profit of 147.2 K can show how well INmune Bio performed in making a profits. Evaluating INmune Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of INmune Bio's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining INmune Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether INmune Bio is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

About INmune Income Statement Analysis

INmune Bio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to INmune Bio shareholders. The income statement also shows INmune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

INmune Bio Income Statement Chart

At present, INmune Bio's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 21.3 M, whereas Selling General Administrative is forecasted to decline to about 6.4 M.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of INmune Bio. It is also known as INmune Bio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most accounts from INmune Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.At present, INmune Bio's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 21.3 M, whereas Selling General Administrative is forecasted to decline to about 6.4 M.
 2010 2023 2024 (projected)
Interest Income77.7K69.9K62.2K
Net Interest Income77.7K69.9K62.2K

INmune Bio income statement Correlations

-0.86-0.86-0.710.710.85-0.86-0.860.340.89-0.87-0.31-0.31-0.65-0.31
-0.861.00.92-0.97-1.01.01.0-0.6-0.971.00.590.590.930.59
-0.861.00.89-0.97-0.991.01.0-0.55-0.981.00.540.540.930.54
-0.710.920.89-0.93-0.930.910.91-0.84-0.840.910.820.820.860.82
0.71-0.97-0.97-0.930.97-0.97-0.970.650.92-0.97-0.65-0.65-0.97-0.65
0.85-1.0-0.99-0.930.97-1.0-1.00.610.96-1.0-0.62-0.62-0.92-0.62
-0.861.01.00.91-0.97-1.01.0-0.58-0.971.00.570.570.930.57
-0.861.01.00.91-0.97-1.01.0-0.56-0.971.00.560.560.930.56
0.34-0.6-0.55-0.840.650.61-0.58-0.560.46-0.56-0.9-0.9-0.51-0.9
0.89-0.97-0.98-0.840.920.96-0.97-0.970.46-0.97-0.39-0.39-0.89-0.39
-0.871.01.00.91-0.97-1.01.01.0-0.56-0.970.560.560.920.56
-0.310.590.540.82-0.65-0.620.570.56-0.9-0.390.561.00.551.0
-0.310.590.540.82-0.65-0.620.570.56-0.9-0.390.561.00.551.0
-0.650.930.930.86-0.97-0.920.930.93-0.51-0.890.920.550.550.55
-0.310.590.540.82-0.65-0.620.570.56-0.9-0.390.561.01.00.55
Click cells to compare fundamentals

INmune Bio Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.18)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.63)
Return On Assets
(0.45)
Return On Equity
(0.99)
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.